A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy: Results of the PolarisDMD TrialRichard S. Finkel, Joanne M. Donovan, M. Tulinius et al.|Journal of Neuromuscular Diseases|2021Cited by 32
Utility of the T-SPOT®.TB test's borderline category to increase test resolution for results around the cut-off pointKaren Rego, William W. Cruikshank, Kristen Pereira et al.|Tuberculosis|2017Cited by 21
Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS‐CMichael Camilleri, Jeffrey M. Johnston, Anthony Lembo et al.|United European Gastroenterology Journal|2014Cited by 17
Effects of EDG-5506, a Fast Myosin Modulator, on Function and Biomarkers of Muscle Damage in Adults with Becker Muscular Dystrophy (S21.002)H. Phan, Joanne M. Donovan, Samuel Collins et al.|Neurology|2024Cited by 3
Sa1094 Developing Benchmarks for Clinically Meaningful Change for IBS-C Symptoms Using Data From Two Phase 3 Trials of LinaclotideBrennan Spiegel, Jeffrey M. Johnston, Giles R. Locke et al.|Gastroenterology|2012Cited by 2